To elucidate the relative contributions of CD4+ and CD8+ T cells to the anti-tumor response, we employed α-CD4 and α-CD8 antibodies to block these cell populations during CR108 + OVA treatment (Figure 6J). Here, CD8A is linked to neoplasm.